Martin van Eickels read more.

Stefan H. Hohnloser, M read more .D., Harry J.G.M. Crijns, M.D., Martin van Eickels, M.D., Christophe Gaudin, M.D., Richard L. Page, M.D., Christian Torp-Pedersen, M.D., and Stuart J. Connolly, M.D. For the ATHENA Investigators: Effect of Dronedarone on Cardiovascular Occasions in Atrial Fibrillation Atrial fibrillation is the most common type of cardiac arrhythmia requiring health care, with a prevalence of almost 1 percent in the adult population in the usa.1 Its prevalence increases with age, affecting 3.8 percent of the U.S. Population over 60 years of age and 9.0 percent of the populace more than 80 years.

Food and Medication Administration on Friday approved an immunotherapy medication for the treatment of advanced non-little cell lung cancer. Keytruda may be used to treat advanced non-little cell lung cancers in patients whose disease has progressed after previous treatments and who’ve tumors that express a proteins called PD-L1, the agency said. Today’s authorization of Keytruda gives physicians the ability to target specific sufferers who may be most likely to reap the benefits of this drug, Dr. Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA’s Center for Medication Evaluation and Analysis, said in an agency news release. The Merck & Co. Drug was approved for make use of with a companion diagnostic test this is the first designed to detect PD-L1 expression in non-little cell lung tumors, the FDA stated in the news release.